Successful Rights Offering for Kadimastem; Raised NIS 5.1M
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Kadimastem to Raise up to NIS 10M in Rights Offering
Kadimastem Received Response from FDA:
Kadimastem Approached the FDA Regarding Its ALS Treatment
Kadimastem to collaborate with Merck Serono to advance efforts in neurodegenerative diseases
Chief Scientist Increases Budget to Advance Kadimastem's Cell Therapy for ALS
Success in Kadimastem’s First Pre-Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS
Kadimastem Receives Approval for U.S. Patent
Leading pharma entrepreneur Avi Meizler believes in Kadimastem!
Kadimastem announces its intention to reduce the exercise price for warrants (Series 1)
Kadimastem Augments the Company's ALS Activities
Kadimastem has received approval from the OCS to promote cell therapy
Merck Serono and Kadimastem MOU on Drug Screening and Discovery for Neurodegenerative Diseases
Kadimastem successfully completes an IPO and raised $5.5 Million USD
Pharmaceutical Company Merck Serono signs an agreement: Use Kadimastem's platform for drug screening
Dr. Eli Opper, joined Kadimastem's team of Advisors
Kadimastem appointed Mr. Ofer Haviv as a director
The new Chief Scientist, Mr. Avi Hasson visits Kadimastem
The Chief Scientist visits Kadimastem